MCQ 1
Question: What is the primary therapeutic use of streptokinase?
A. Antiplatelet therapy
B. Thrombolytic therapy
C. Anticoagulant therapy
D. Anti-inflammatory therapy
E. Antihypertensive therapy
Click here to see the answer
Answer: B. Thrombolytic therapy
Explanation: Streptokinase is primarily used for thrombolytic therapy to dissolve blood clots in patients with conditions such as myocardial infarction, pulmonary embolism, and deep vein thrombosis.
MCQ 2
Question: Streptokinase exerts its thrombolytic effect by activating which enzyme?
A. Thrombin
B. Plasminogen
C. Factor Xa
D. Fibrinogen
E. Prothrombin
Click here to see the answer
Answer: B. Plasminogen
Explanation: Streptokinase activates plasminogen to plasmin, an enzyme that breaks down fibrin clots, thus exerting its thrombolytic effect.
MCQ 3
Question: Which of the following is a major contraindication for the use of streptokinase?
A. Recent major surgery
B. Mild hypertension
C. Controlled diabetes mellitus
D. Chronic stable angina
E. Hyperlipidemia
Click here to see the answer
Answer: A. Recent major surgery
Explanation: Recent major surgery is a major contraindication for the use of streptokinase due to the increased risk of severe bleeding.
MCQ 4
Question: Which adverse effect is most commonly associated with streptokinase therapy?
A. Hypertension
B. Bleeding
C. Hyperglycemia
D. Bradycardia
E. Hypokalemia
Click here to see the answer
Answer: B. Bleeding
Explanation: The most common adverse effect associated with streptokinase therapy is bleeding, which can range from minor to severe, including intracranial hemorrhage.
MCQ 5
Question: In the management of acute myocardial infarction, how soon after symptom onset should streptokinase be administered for optimal efficacy?
A. Within 1 hour
B. Within 3 hours
C. Within 6 hours
D. Within 12 hours
E. Within 24 hours
Click here to see the answer
Answer: C. Within 6 hours
Explanation: Streptokinase should be administered as soon as possible, ideally within 6 hours of symptom onset, for optimal efficacy in the management of acute myocardial infarction.
MCQ 6
Question: What is the mechanism of action of streptokinase in thrombolytic therapy?
A. Directly degrading fibrin
B. Activating plasminogen to plasmin
C. Inhibiting platelet aggregation
D. Inactivating thrombin
E. Blocking factor Xa
Click here to see the answer
Answer: B. Activating plasminogen to plasmin
Explanation: Streptokinase acts by binding to plasminogen, converting it to plasmin, which then breaks down fibrin clots.
MCQ 7
Question: What is an important consideration when re-administering streptokinase to a patient?
A. Increased efficacy
B. Decreased efficacy due to antibody formation
C. Reduced risk of bleeding
D. No change in therapeutic effect
E. Increased risk of hypotension
Click here to see the answer
Answer: B. Decreased efficacy due to antibody formation
Explanation: When streptokinase is re-administered, there is a risk of decreased efficacy due to the formation of antibodies against the drug, which can neutralize its thrombolytic effect.
MCQ 8
Question: Which patient population should avoid the use of streptokinase due to a high risk of allergic reactions?
A. Patients with a history of streptococcal infections
B. Patients with a history of hypertension
C. Patients with controlled diabetes
D. Patients with hyperlipidemia
E. Patients with hypothyroidism
Click here to see the answer
Answer: A. Patients with a history of streptococcal infections
Explanation: Patients with a history of streptococcal infections may have antibodies against streptokinase, increasing the risk of allergic reactions when the drug is administered.
MCQ 9
Question: Which laboratory test should be monitored closely during streptokinase therapy?
A. Complete blood count (CBC)
B. Serum electrolytes
C. Coagulation profile (e.g., PT, aPTT)
D. Liver function tests (LFTs)
E. Renal function tests
Click here to see the answer
Answer: C. Coagulation profile (e.g., PT, aPTT)
Explanation: Monitoring the coagulation profile, including prothrombin time (PT) and activated partial thromboplastin time (aPTT), is crucial during streptokinase therapy to assess the risk of bleeding and adjust treatment as necessary.
MCQ 10
Question: What is a common indication for the use of streptokinase?
A. Chronic stable angina
B. Acute myocardial infarction
C. Primary hypertension
D. Type 2 diabetes mellitus
E. Chronic obstructive pulmonary disease (COPD)
Click here to see the answer
Answer: B. Acute myocardial infarction
Explanation: Streptokinase is commonly indicated for the treatment of acute myocardial infarction to dissolve blood clots and restore blood flow to the affected area of the heart.
MCQ 11
Question: What is the primary therapeutic use of tissue plasminogen activators (tPAs)?
A. Antiplatelet therapy
B. Thrombolytic therapy
C. Anticoagulant therapy
D. Anti-inflammatory therapy
E. Antihypertensive therapy
Click here to see the answer
Answer: B. Thrombolytic therapy
Explanation: Tissue plasminogen activators (tPAs) are used primarily for thrombolytic therapy to dissolve blood clots in conditions such as myocardial infarction, pulmonary embolism, and ischemic stroke.
MCQ 12
Question: Which of the following is an example of a tissue plasminogen activator (tPA)?
A. Clopidogrel
B. Warfarin
C. Alteplase
D. Heparin
E. Aspirin
Click here to see the answer
Answer: C. Alteplase
Explanation: Alteplase is an example of a tissue plasminogen activator (tPA) used to break down blood clots in thrombolytic therapy.
MCQ 13
Question: What is the mechanism of action of tissue plasminogen activators (tPAs)?
A. Inhibiting platelet aggregation
B. Activating plasminogen to plasmin
C. Blocking factor Xa
D. Inactivating thrombin
E. Directly degrading fibrin
Click here to see the answer
Answer: B. Activating plasminogen to plasmin
Explanation: Tissue plasminogen activators (tPAs) work by converting plasminogen to plasmin, which then degrades fibrin clots.
MCQ 14
Question: Which of the following is a major contraindication for the use of tPAs?
A. Chronic stable angina
B. Recent major surgery
C. Hyperlipidemia
D. Controlled hypertension
E. Type 2 diabetes mellitus
Click here to see the answer
Answer: B. Recent major surgery
Explanation: Recent major surgery is a major contraindication for the use of tPAs due to the increased risk of severe bleeding.
MCQ 15
Question: In the management of acute ischemic stroke, how soon after symptom onset should tPAs be administered for optimal efficacy?
A. Within 1 hour
B. Within 3 hours
C. Within 6 hours
D. Within 12 hours
E. Within 24 hours
Click here to see the answer
Answer: B. Within 3 hours
Explanation: tPAs should be administered as soon as possible, ideally within 3 hours of symptom onset, for optimal efficacy in the management of acute ischemic stroke.
MCQ 16
Question: Which adverse effect is most commonly associated with tPA therapy?
A. Hyperglycemia
B. Bleeding
C. Hypotension
D. Bradycardia
E. Hyperkalemia
Click here to see the answer
Answer: B. Bleeding
Explanation: The most common adverse effect associated with tPA therapy is bleeding, which can range from minor to severe, including intracranial hemorrhage.
MCQ 17
Question: What is an important consideration when administering tPAs to a patient with a history of recent trauma?
A. Increased efficacy
B. Decreased risk of bleeding
C. Increased risk of bleeding
D. Enhanced therapeutic effect
E. Reduced therapeutic effect
Click here to see the answer
Answer: C. Increased risk of bleeding
Explanation: Patients with a history of recent trauma have an increased risk of bleeding when administered tPAs, and this risk must be carefully considered before initiating therapy.
MCQ 18
Question: Which laboratory test should be closely monitored during tPA therapy?
A. Complete blood count (CBC)
B. Serum electrolytes
C. Coagulation profile (e.g., PT, aPTT)
D. Liver function tests (LFTs)
E. Renal function tests
Click here to see the answer
Answer: C. Coagulation profile (e.g., PT, aPTT)
Explanation: Monitoring the coagulation profile, including prothrombin time (PT) and activated partial thromboplastin time (aPTT), is crucial during tPA therapy to assess the risk of bleeding and adjust treatment as necessary.
MCQ 19
Question: Which of the following is a common indication for the use of tissue plasminogen activators (tPAs)?
A. Chronic stable angina
B. Acute ischemic stroke
C. Primary hypertension
D. Type 2 diabetes mellitus
E. Chronic obstructive pulmonary disease (COPD)
Click here to see the answer
Answer: B. Acute ischemic stroke
Explanation: tPAs are commonly indicated for the treatment of acute ischemic stroke to dissolve blood clots and restore blood flow to the affected area of the brain.
MCQ 20
Question: What is the expected outcome of successful tPA therapy in a patient with an acute myocardial infarction?
A. Reduction in cholesterol levels
B. Restoration of blood flow to the affected coronary artery
C. Decrease in blood pressure
D. Increase in heart rate
E. Reduction in blood glucose levels
Click here to see the answer
Answer: B. Restoration of blood flow to the affected coronary artery
Explanation: The expected outcome of successful tPA therapy in a patient with an acute myocardial infarction is the restoration of blood flow to the affected coronary artery, which can help limit the extent of heart damage and improve survival rates.